The INTEGRIS-IPF clinical trial is studying PLN-74809, an oral investigational medicine designed to directly target the development of lung fibrosis (when tissue becomes damaged and scarred, affecting normal function of the organ). The medicine has been tested in over 280 individuals and was well tolerated. It is taken orally once per day for 12 weeks.
By stopping the cellular process that causes fibrosis, PLN-74809 may have the potential to slow or stop the progressive decline in lung function that happens with idiopathic pulmonary fibrosis, or IPF. This study will help establish the PLN-74809 safety profile and provide early insights on whether it affects the progression of the disease.
What to expect in the INTEGRIS-IPF clinical trial
The study will consist of:
- Practical visit schedule with monthly visits starting at week 4
- 75% of participants receive active study drug and 25% receive placebo
- Short study duration including:
- A screening period, up to 28 days
- A treatment period of 12 weeks
- A follow-up period of 2 weeks
During the study period, you will have a total of seven visits to assess safety and lung function, including detailed lung imaging. Some of these visits will be on site with your doctors. You will continue to receive standard of care treatment during the duration of your participation in the clinical trial.
Can I participate?
Talk to your doctor about participating in this clinical trial if:
- You are a patient with confirmed diagnosis of idiopathic pulmonary fibrosis
- You are over the age of 40
If you are currently taking an IPF medication, like nintedanib or pirfenidone, you may enroll in this study and continue to take this medication.
- The trial is open to women and men
- The trial will include 60 study sites across the U.S. and the rest of the world
COVID-19 Impact
We are committed to protecting patients and clinicians from the spread of COVID-19. Our clinical trial sites are following all government and institutional safety guidelines.
Pliant Therapeutics will continue to work closely with site investigators and update our practices accordingly to ensure the safe continuation of the trial.